Haemonetics Co. (NYSE:HAE) to Post FY2025 Earnings of $4.56 Per Share, Zacks Research Forecasts

Haemonetics Co. (NYSE:HAE) – Equities research analysts at Zacks Research raised their FY2025 earnings per share estimates for Haemonetics in a report released on Thursday, September 12th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $4.56 per share for the year, up from their prior estimate of $4.55. The consensus estimate for Haemonetics’ current full-year earnings is $4.58 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.22 EPS, Q3 2026 earnings at $1.23 EPS, Q4 2026 earnings at $1.41 EPS and FY2026 earnings at $5.11 EPS.

Other equities research analysts have also issued reports about the company. Citigroup reduced their target price on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Wednesday, June 12th. Barrington Research lifted their target price on shares of Haemonetics from $107.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Bank of America initiated coverage on shares of Haemonetics in a report on Wednesday. They set a “neutral” rating and a $85.00 price target for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.50.

Haemonetics Price Performance

NYSE HAE opened at $73.26 on Friday. The firm has a market cap of $3.75 billion, a P/E ratio of 31.99, a price-to-earnings-growth ratio of 1.32 and a beta of 0.30. The stock’s 50-day moving average is $81.55 and its two-hundred day moving average is $83.87. Haemonetics has a fifty-two week low of $70.74 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The business had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. During the same quarter last year, the company earned $1.05 EPS. The business’s revenue for the quarter was up 8.0% compared to the same quarter last year.

Insiders Place Their Bets

In other news, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the transaction, the insider now owns 18,196 shares of the company’s stock, valued at $1,658,565.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of Haemonetics stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now owns 21,410 shares in the company, valued at $1,926,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the transaction, the insider now owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The disclosure for this sale can be found here. Company insiders own 1.80% of the company’s stock.

Institutional Trading of Haemonetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Thrivent Financial for Lutherans lifted its stake in Haemonetics by 6,573.6% during the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock worth $70,267,000 after purchasing an additional 836,623 shares during the period. Silvercrest Asset Management Group LLC acquired a new position in shares of Haemonetics in the 1st quarter worth approximately $38,706,000. Mizuho Markets Americas LLC bought a new position in shares of Haemonetics during the 2nd quarter worth approximately $30,080,000. Norges Bank acquired a new stake in Haemonetics in the 4th quarter valued at $28,591,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in Haemonetics by 132.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock valued at $42,930,000 after buying an additional 286,897 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.